Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4343373 | 0.86 | ROCK2 (0.40) | MAPK1ROCK2ROCK1LRRK2JAK2 | |
| SCHEMBL4343155 | 0.83 | NTRK1 (0.47) | NTRK1MAPK1ROCK2ROCK1TRPV3 | |
| SCHEMBL5031154 | 0.83 | TRPV3 (0.41) | MAPK1ROCK2ROCK1TRPV3 | |
| SCHEMBL4343211 | 0.81 | MAP4K4 (0.45) | NTRK1LRRK2TTKJAK2JAK3 | |
| SCHEMBL2864633 | 0.81 | MAP2K4 (0.47) | NTRK1MAPK1LRRK2TTK | |
| SCHEMBL2861298 | 0.80 | DYRK1A (0.49) | NTRK1LRRK2 | |
| SCHEMBL27558580 | 0.79 | MAPK1 (0.54) | MAPK1 | |
| SCHEMBL2859833 | 0.79 | MAPK1 (0.54) | MAPK1 | |
| SCHEMBL4327632 | 0.78 | MKNK1 (0.47) | ROCK2ROCK1JAK2JAK3 | |
| SCHEMBL4341447 | 0.78 | JAK2 (0.40) | MAPK1ROCK2ROCK1TRPV3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | NTRK1 1241/4885MAPK1 1/4885ROCK2 805/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | NTRK1 1241/4885MAPK1 1/4885ROCK2 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.